Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22230898 | 1.00 | FFAR3 (0.30) | FFAR3 | |
| SCHEMBL22230897 | 1.00 | FFAR3 (0.30) | FFAR3 | |
| SCHEMBL30067752 | 0.94 | — | — | |
| SCHEMBL30067765 | 0.82 | — | — | |
| SCHEMBL30068011 | 0.77 | MEN1 (0.30) | — | |
| SCHEMBL14023905 | 0.77 | L3MBTL1 (0.33) | — | |
| SCHEMBL29530324 | 0.76 | GRIN2B (0.33) | — | |
| SCHEMBL11963181 | 0.75 | GRIN2B (0.41) | — | |
| SCHEMBL8344035 | 0.75 | GRIN2B (0.41) | — | |
| SCHEMBL705138 | 0.75 | GRIN2B (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12006289-B2 | Potassium channel inhibitors | SANIONA A/S (DK) | 2024-06-11 | — | — | US | disclosed |
| US-20230364070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ANTARES THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| CN-116997549-A | Pyrrolo [3,2-C ] pyridin-4-one derivatives for the treatment of cancer | 蝎子疗法股份有限公司 | 2023-11-03 | — | — | CN | disclosed |
| EP-4217070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Scorpion Therapeutics, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-20220169602-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SANIONA A/S (DK) | 2022-06-02 | — | — | US | disclosed |
| US-20220169605-A1 | NOVEL SUBSTITUTED SULFONYLUREA DERIVATIVES | ZYDUS LIFESCIENCES LIMITED (IN) | 2022-06-02 | — | — | US | disclosed |
| EP-3941903-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | Saniona A/S (DK) | 2022-01-26 | — | — | EP | disclosed |
| EP-3911631-A1 | NOVEL SUBSTITUTED SULFONYLUREA DERIVATIVES | Cadila Healthcare Limited (IN) | 2021-11-24 | — | — | EP | disclosed |
| CN-113474333-A | Novel substituted sulfonylurea derivatives | 卡迪拉保健有限公司 | 2021-10-01 | — | — | CN | disclosed |
| WO-2020193419-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | SANIONA A/S (DK) | 2020-10-01 | — | — | WO | disclosed |
| WO-2020148619-A1 | NOVEL SUBSTITUTED SULFONYLUREA DERIVATIVES | CADILA HEALTHCARE LIMITED (IN) | 2020-07-23 | — | — | WO | disclosed |
| EP-2114942-B1 | NOVEL AMINOPYRIMIDINE DERIVATIVES AS PLK1 INHIBITORS | MSD KK (JP) | 2012-10-31 | — | — | EP | disclosed |
| EP-2116543-A1 | NOVEL AMINOPYRIMIDINE DERIVATIVE AS PLK1 INHIBITOR | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-11-11 | — | — | EP | disclosed |
| EP-2114942-A1 | NOVEL AMINOPYRIMIDINE DERIVATIVES AS PLK1 INHIBITORS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
| WO-2008081910-A1 | NOVEL AMINOPYRIMIDINE DERIVATIVES AS PLK1 INHIBITORS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220169605-A1 | NOVEL SUBSTITUTED SULFONYLUREA DERIVATIVES | NOD1, NLRP3, IL1R1 | FFAR3 73/4885 |
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | PLK1, AURKA, CDK1 | FFAR3 3220/4885 |
| US-20220169602-A1 | NOVEL POTASSIUM CHANNEL INHIBITORS | KCNN2, KCNJ2, KCNN1 | FFAR3 1896/4885 |
| US-12006289-B2 | Potassium channel inhibitors | KCNJ2, KCNN2, KCNN1 | FFAR3 2156/4885 |
| US-20230364070-A1 | PYRROLO[3,2-C]PYRIDIN-4-ONE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ERBB2, EGFR, ERBB3 | FFAR3 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.